

1 **Optimizing direct RT-LAMP to detect transmissible SARS-**  
2 **CoV-2 from primary nasopharyngeal swab and saliva**  
3 **patient samples**

4

5 Dawn M. Dudley<sup>1</sup>, Christina M. Newman<sup>1</sup>, Andrea M. Weiler<sup>2</sup>, Mitchell D.

6 Ramuta<sup>1</sup>, Cecilia G. Shortreed<sup>1</sup>, Anna S. Heffron<sup>1</sup>, Molly A. Accola<sup>3</sup>, William M.

7 Rehrauer<sup>3</sup>, Thomas C. Friedrich<sup>4</sup>, and \*David H. O'Connor<sup>1</sup>

8

9 <sup>1</sup>Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison,

10 Madison, WI, USA, <sup>2</sup>Wisconsin National Primate Research Center, University of Wisconsin-

11 Madison, Madison, WI, USA, <sup>3</sup>University of Wisconsin Hospitals and Clinics, Madison, WI,

12 USA <sup>4</sup>Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI,

13 USA.

14

15 \*Corresponding author email [dhocconno@wisc.edu](mailto:dhocconno@wisc.edu)

16

17 Short title: RT-LAMP detection of SARS-CoV-2 from NP swab and saliva samples

18

## 19 **Abstract**

20 SARS-CoV-2 testing is crucial to controlling the spread of this virus, yet shortages of nucleic  
21 acid extraction supplies and other key reagents have hindered the response to COVID-19 in the  
22 US. Several groups have described loop-mediated isothermal amplification (LAMP) assays for  
23 SARS-CoV-2, including testing directly from nasopharyngeal swabs and eliminating the need for  
24 reagents in short supply. Here we describe a fluorescence-based RT-LAMP test using direct  
25 nasopharyngeal swab samples and show consistent detection in clinically confirmed samples,  
26 albeit with approximately 100-fold lower sensitivity than qRT-PCR. We demonstrate that adding  
27 lysis buffer directly into the RT-LAMP reaction improves the sensitivity of some samples by  
28 approximately 10-fold. Overall, the limit of detection (LOD) of RT-LAMP using direct  
29 nasopharyngeal swab or saliva samples without RNA extraction is  $1 \times 10^5$ - $1 \times 10^6$  copies/ml. This  
30 LOD is sufficient to detect samples from which infectious virus can be cultured. Therefore,  
31 samples that test positive in this assay contain levels of virus that are most likely to perpetuate  
32 transmission. Furthermore, purified RNA in this assay achieves a similar LOD to qRT-PCR and  
33 we provide a revised method to work directly with saliva as starting material. These results  
34 indicate that high-throughput RT-LAMP testing could augment qRT-PCR in SARS-CoV-2  
35 screening programs, especially while the availability of qRT-PCR testing and RNA extraction  
36 reagents is constrained.

37

## 38 **Introduction**

39 There are more than 5.8 million reported severe acute respiratory syndrome coronavirus 2  
40 (SARS-CoV-2) infections in the United States as of August 27, 2020  
41 (<https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>). The actual  
42 number of infections is likely far greater since testing remains limited. We now understand that  
43 asymptomatic individuals contain similar levels of SARS-CoV-2 in the upper respiratory tract as  
44 symptomatic individuals (1–6). Furthermore, 17 out of 24 (71%) presymptomatic patients had positive  
45 viral cultures 1 to 6 days before the onset of symptoms (1). Symptom-based screening is not  
46 sufficient for controlling SARS-CoV-2 transmission and emphasizes the need for expanded  
47 nucleic acid screening of asymptomatic/presymptomatic individuals.

48 Identifying individuals shedding the most SARS-CoV-2 virus is critical for interrupting  
49 transmission. The threshold of virus in a patient sample required to isolate and grow the virus in  
50 tissue culture is one indicator of the viral load necessary to transmit the virus. Recent virological  
51 assessments of COVID-19 patients suggest that virus isolation from patient samples is dependent  
52 on viral load and sample type (1, 7–9). Wölfel et al. (7) demonstrated that successful SARS-  
53 CoV-2 isolation was limited to only NP swabs and sputum that had viral loads greater than  $1 \times 10^6$   
54 copies of viral RNA (vRNA)/ml (7). This same virus isolation threshold of  $1 \times 10^6$  vRNA  
55 copies/ml was also found by Van Kampen et al. (10) when analyzing 129 severe COVID-19  
56 patient samples and Quicke et al. (11) in a longitudinal surveillance study of 454 skilled nursing  
57 facility staff members. During a SARS-CoV-2 outbreak in a Washington nursing home, virus  
58 could be isolated only from NP swabs with RT-PCR cycle threshold (Ct) values of less than 30,  
59 with few exceptions, collected from patients presenting as asymptomatic, presymptomatic, with  
60 typical and atypical symptoms (1). A similar virus isolation threshold (Ct value 33-34;

61 approximately  $1 \times 10^5$  RNA copies/ml) was observed in SARS-CoV-2 patients by La Scola et al.  
62 (2020) when using a qRT-PCR assay targeting E gene (12). In a recent non-human primate  
63 study, virus was successfully isolated from the upper respiratory tract of rhesus macaques  
64 inoculated with  $2.6 \times 10^6$  TCID<sub>50</sub> of SARS-CoV-2 via a combination of intratracheal, intranasal,  
65 ocular, and oral routes (9). Positive viral cultures were limited to NP and oral swabs with greater  
66 than  $1 \times 10^6$  and  $1 \times 10^5$  copies/ml respectively (9). These data suggest that diagnostic tests with a  
67 sensitivity around  $1 \times 10^6$  copies/ml are sufficient for capturing culture-positive cases with the  
68 greatest transmission risk.

69 Conventional SARS-CoV-2 testing relies on RT-PCR amplification of virus-specific  
70 nucleic acids extracted from nasopharyngeal (NP) swabs. However, shortages of nucleic acid  
71 extraction and RT-PCR reagents as well as RT-PCR instrumentation remain a problem (13).  
72 Alternative nucleic acid extraction methods and "direct" testing that does not require nucleic acid  
73 extraction are important to expand testing while reducing time and cost. Indeed, the SalivaDirect  
74 method recently approved under an FDA EUA, utilizes saliva without RNA extraction into a RT-  
75 PCR assay, eliminating at least part of the process experiencing shortages (14).

76 Loop-mediated isothermal amplification (LAMP) has been used as a tool for point-of-  
77 need diagnostic testing for several pathogens, including SARS-CoV-2 (15–24). LAMP assays  
78 are an alternative method for rapidly detecting the presence of specific nucleic acids in samples,  
79 with colorimetric or fluorescent visualization of results. LAMP assays are inexpensive, high-  
80 throughput, do not necessarily require nucleic acid purification, and give rapid results. These  
81 previously published manuscripts demonstrate proof-of-principle for SARS-CoV-2 testing by  
82 RT-LAMP using either contrived samples with free nucleic acid or primary samples with RNA  
83 isolation first.

84           In this study, we focused on characterizing and optimizing direct RT-LAMP without  
85 RNA isolation and with primary NP swab samples with known SARS-CoV-2 status. We  
86 demonstrate the limit of detection (LOD) of direct swab RT-LAMP in primary swab samples as  
87 well as modifications of the technique that help improve sensitivity, but don't rely on the same  
88 materials required for traditional qRT-PCR methods. We characterized the use of Lucigen  
89 QuickExtract (QE) lysis buffer, guanidine hydrochloride addition, an alternative RNA isolation  
90 method, and several primer sets and combinations targeting different gene regions. Lastly, we  
91 used our optimized approach to test the transition to direct RT-LAMP with saliva in a point-of-  
92 need testing approach. Each of these modifications are useful additions to the SARS-CoV-2  
93 testing repertoire and have unique benefits for testing in multiple laboratory settings.  
94 Furthermore, we suggest that the limit of sensitivity achieved with any of these methods is  
95 sufficient to detect levels of virus that can be cultured out of samples and therefore represents  
96 levels where transmission is most likely and self-quarantine most important.

## 97 **Materials and Methods**

### 98 **Sample collection**

99 Residual NP swab and saliva samples were provided by University of Wisconsin-Madison  
100 Hospitals and Clinics and the Wisconsin State Laboratory of Hygiene under biosafety protocol  
101 B00000117 (IRB 2016-0605) and their use was not considered human subjects research by the  
102 University of Wisconsin-Madison School of Medicine and Public Health's Institutional Review  
103 Board. Samples were collected into a variety of transport media including universal transport  
104 media (UTM), viral transport media (VTM), and phosphate buffered saline (PBS), stored at 4°C

105 for up to 7 days, and transported to the laboratory at room temperature. Upon arrival at the  
106 laboratory, samples were stored at either 4°C (for immediate same-day use) or -80°C until use in  
107 RT-PCR or RT-LAMP assays. Residual saliva samples contained no media/buffer and were  
108 stored for 2-4 weeks at 4°C before arriving in the lab and were tested within 2 days of arrival.

## 109 **qRT-PCR**

110 Viral load analysis was performed after samples arrived in our laboratory. RNA was isolated  
111 using the Viral Total Nucleic Acid kit for the Maxwell RSC instrument (Promega, Madison, WI)  
112 following the manufacturer's instructions. Saliva samples were diluted 1:1 in water prior to  
113 extraction. Viral load quantification was performed using a qRT-PCR assay developed by the  
114 CDC to detect SARS-CoV-2 (specifically the N1 assay) and commercially available from IDT  
115 (Coralville, IA). The assay was run on a LightCycler 96 or LC480 instrument (Roche,  
116 Indianapolis, IN) using the Taqman Fast Virus 1-step Master Mix enzyme (Thermo Fisher,  
117 Waltham, MA). The LOD of this assay is estimated to be 200 genome equivalents/ml saliva or  
118 swab fluid. To determine the viral load, samples were interpolated onto a standard curve  
119 consisting of serial 10-fold dilutions of *in vitro* transcribed SARS-CoV-2 N gene RNA kindly  
120 provided by Nathan Grubaugh (Yale University).

## 121 **RT-LAMP**

122 The experiments we describe here were modified from the SARS-CoV-2 RT-LAMP assay  
123 developed by Zhang et al. (16). For most assays we used fluorescent-based detection with  
124 Warmstart LAMP reagents and the included fluorescent dye (New England Biolabs, NEB). We  
125 tested primer sets developed in previous studies targeting several SARS-CoV-2 genes as shown

126 in S1 Table (16, 17, 25–29). Of note, the Color-Orf1a primers and Lamb-Orf1a primers are  
127 identical, but were used at different concentrations per the protocols developed by each lab. The  
128 final 1X primer concentrations are listed in the table. For each reaction, a 10X stock of all 6  
129 primers were combined with Warmstart mastermix and water in 25 $\mu$ l reactions following the  
130 manufacturer's recommendations. Unless otherwise stated, 1 $\mu$ l RNA transcript of the SARS-  
131 CoV-2 N-gene obtained by Dr. Nathan Grubaugh, 1 $\mu$ l of synthetic SARS-CoV-2 RNA transcript  
132 (Twist Biosciences; RNA control 2), 1 $\mu$ l of gamma-irradiated SARS-CoV-2 (BEI; NR-52287;  
133 isolate USA-WA1/2020), or 1 $\mu$ l primary NP swab sample were tested in each RT-LAMP  
134 reaction. Unless otherwise stated, all serial dilutions were performed in water. For reactions  
135 testing guanidine hydrochloride addition to the RT-LAMP mastermix, a final concentration of  
136 40mM stock was used in the mastermix. Except where otherwise specified, samples were run on  
137 a Roche Lightcycler 96 instrument (Roche Diagnostics) using an 80-cycle program with the  
138 SYBR Green channel at 65°C (495-497 nm absorption; 517-520 nm emission) and data  
139 collection every 30 seconds. For experiments determining the appropriate volume of direct swab  
140 sample addition for highest RT-LAMP efficiency, a 60-cycle program with data collection every  
141 20 seconds was used. For colorimetric RT-LAMP with saliva, saliva was incubated at 65°C for  
142 30 minutes followed by 98°C for 3 minutes in a heat block. Saliva was then diluted 1:1 in PBS  
143 and 3 $\mu$ l was added into a 20 $\mu$ l RT-LAMP mastermix containing the Color-N primer set and  
144 colorimetric mastermix (NEB) and incubated at 65°C for 30 minutes.

## 145 **Sample lysis**

146 A subset of samples was treated with LucigenQE RNA Extraction Solution (Lucigen, Middleton,  
147 WI) in a 1:1 ratio as described in Ladha et al. (30). Briefly, NP swab eluate was combined with

148 an equivalent volume of LucigenQE and briefly vortexed. Samples were then incubated for 5  
149 minutes at 95°C, cooled on ice, and maintained until addition to the RT-LAMP reaction.

## 150 **Statistical analysis**

151 To assess improvement in quantification cycle (Cq) values using sample lysis with LucigenQE  
152 or RNA isolation, mean Cq values were calculated for each sample. Mean Cq values were not  
153 normally distributed for either dataset so we used a nonparametric equivalent to a paired t-test,  
154 the Wilcoxon signed rank test with continuity correction, for each set of paired samples.

155 To examine whether sample vRNA load and/or treatment were significantly associated  
156 with a positive RT-LAMP result, we used logistic regression with RT-LAMP result as the  
157 dependent variable. For our analysis, an equivocal result in which one replicate was positive  
158 while the other was negative, was conservatively treated as negative. We coded RT-LAMP  
159 results for each sample tested by each method as a dichotomous outcome with positive samples  
160 coded as “1” and negative or equivocal samples coded as “0”. For explanatory variables, we  
161 chose qRT-PCR vRNA load, with samples greater than  $10^6$  copies/ml coded as “1” and samples  
162 less than  $10^6$  copies/ml coded as “0”, and group, designated as either 5µl RNA, 1µl lysed, or 1µl  
163 direct addition.

164 All statistical analyses were performed in RStudio (v. 1.2.1335) using R (v. 3.6.0) (31).



## 165 **Results**

### 166 **Limit of detection with RNA transcript and Gene-N-A primers**

167 To determine a limit of detection for the RT-LAMP assay, serial 10-fold dilutions of RNA  
168 transcript containing the N-gene were tested in RT-LAMP reactions with Gene-N-A primers in  
169 duplicate in 3 independent assays. RNA transcripts were diluted in RNase-free water. Consistent  
170 detection of RNA was achieved when  $1 \times 10^6$  copies or greater of RNA/ml was added into the  
171 reactions ( $1 \times 10^3$  copies/ $\mu$ l per reaction) (Fig 1A). To obtain a more precise LOD, transcript was  
172 diluted 1:2 starting at  $5 \times 10^6$  copies/ml down to  $7.8 \times 10^4$  copies/ml and each concentration was  
173 run in 10 replicates. Nine of ten replicates at  $6.25 \times 10^5$  copies/ml were positive, while 6/10 were  
174 positive at  $3.12 \times 10^5$  copies/ml and 5/10 were positive at  $1.56 \times 10^5$  copies/ml (Fig 1A). Thus, we  
175 can consistently detect 625 copies of input into the reaction, but can detect down to 156 copies of  
176 input in half of the reactions. Zero reactions were detected as positive at  $1 \times 10^5$  copies/ml (100  
177 copies/reaction) or below.

178

### 179 **Fig 1: Detection of SARS-CoV-2 by RT-LAMP from transcript or primary NP swab**

180 **samples.** A. The quantification cycle (Cq) relative to each transcript copy number is plotted.  
181 Samples that were not detectable were plotted on the line labeled ND for all graphs at Cq of 60  
182 or 80, the total number of cycles run in our assays. The vertical line is set at the lowest dilution  
183 where positive samples were detected using the transcript input for all graphs (156,300 vRNA  
184 copies/ml). Each replicate is plotted on all graphs. B. Detection of 106 SARS-CoV-2 positive  
185 primary NP swab samples relative to their in-house viral load value. C. RT-LAMP Cq of five  
186 SARS-CoV-2 positive primary NP swab samples with different swab input volumes.

## 187 **Limit of detection with primary nasopharyngeal swab samples**

188 Leftover NP swab samples from 106 patients with known clinical diagnosis of SARS-CoV-2  
189 were tested directly by RT-LAMP in duplicate. Additionally, RNA was isolated from these  
190 samples and tested by qRT-PCR with a transcript standard for quantitation. A total of 63/106  
191 (59%) samples tested positive by RT-LAMP and 106/106 by qRT-PCR (S2 Table). Another 13  
192 samples were equivocal by RT-LAMP, with one of two replicates positive. As shown in Fig 1B,  
193 the LOD of primary samples was similar to that seen with RNA transcript. 63/77 (82%) samples  
194 with viral RNA copy numbers greater than  $1 \times 10^6$  copies/ml were detected by RT-LAMP,  
195 whereas 0/28 samples with concentrations  $< 1 \times 10^6$  were detected positive and 3/28 were  
196 equivocal. All 31 samples that tested negative for SARS-CoV-2 by clinical laboratories also  
197 tested negative by RT-LAMP (data not shown).

## 198 **RT-LAMP is inhibited by adding larger volumes of primary sample**

199 To determine whether adding larger volumes of primary NP swab samples could improve the  
200 sensitivity of the assay, 1, 3, and 5  $\mu$ l of swab samples from 5 primary SARS-CoV-2-positive  
201 samples were tested side-by-side. All replicates were detected as positive when 1  $\mu$ l was added  
202 directly into the RT-LAMP reaction (Fig 1C). However, one of the two replicates from two  
203 samples tested negative when 3  $\mu$ l of sample was added and both replicates from one sample  
204 tested negative when 5  $\mu$ l of sample was added into the RT-LAMP reaction. Furthermore, Cq  
205 thresholds were higher with addition of higher volumes of sample. Therefore, we chose to use  
206 1  $\mu$ l of straight swab sample in subsequent experiments.

## 207 **Lysis buffer improves the sensitivity of RT-LAMP**

208 To determine whether treatment with lysis buffer improves the sensitivity of RT-LAMP to detect  
209 SARS-CoV-2 in clinical samples without the use of traditional nucleic acid isolation methods,  
210 we treated 72 clinical samples with a range of SARS-CoV-2 vRNA loads in a 1:1 ratio with  
211 LucigenQE as described by Ladha et al. (30). We then compared the fluorescent RT-LAMP C<sub>q</sub>  
212 values between 1µl of lysed sample and 1µl of the same samples added directly. Addition of 1µl  
213 of NP swab eluate directly into the RT-LAMP reaction resulted in positive detection in both  
214 replicates of 46/72 (64%) known SARS-CoV-2-positive samples and in 1 of 2 replicates in 6  
215 additional samples (Fig 2A, S2 Table ). Treatment of the same 72 samples with LucigenQE  
216 resulted in detection of both replicates for 56/72 (78%) samples, an additional 10 samples that  
217 were undetectable before. An additional 4 samples that were negative when tested directly were  
218 equivocal when treated with LucigenQE. Negative samples with either method occurred in  
219 samples with viral loads ranging from  $1.0 \times 10^4$ - $6.19 \times 10^8$  vRNA copies/ml. However, while 0/19  
220 samples with viral loads below  $1 \times 10^6$  were positive with 1µl straight, 4 of 19 samples were  
221 detectable after lysis in both replicates and 4 additional samples were detected in 1 of 2  
222 replicates. Mean C<sub>q</sub> for LucigenQE-treated samples were significantly lower (C<sub>q</sub> = 38.62) than  
223 those for directly added samples (C<sub>q</sub> = 49.08) (Wilcoxon signed rank test, V = 1830, p =  $1.67 \times 10^{-11}$ ),  
224 suggesting that lysis treatment improves the efficiency of amplification in the LAMP reaction  
225 (Fig 2A). We also examined whether sample vRNA load and/or treatment were significantly  
226 associated with RT-LAMP detection results. We found that direct addition of 1µl of untreated  
227 NP swab was associated with a decreased odds of detecting a positive RT-LAMP result (OR =  
228 0.20, 95%CI = 0.04-0.65, p = 0.015) while the most important factor associated with a positive

229 result was a sample vRNA load of greater than  $10^6$  copies/ml (OR = 88.5, 95%CI = 25.74-  
230 434.87,  $p = 1.88E^{-10}$ ).

231

232 **Fig 2: Comparison of the detection of SARS-CoV-2 positive primary NP swab samples**

233 **after using direct sample addition to either LucigenQE treatment or isolated vRNA. A.**

234 Comparison of Cq values between samples treated with or without LucigenQE and run by RT-

235 LAMP with 1 $\mu$ l of sample. B. Comparison of Cq values between RT-LAMP assays run with 1 $\mu$ l

236 straight swab or 5 $\mu$ l of isolated and purified vRNA.

237

238 **RNA isolation improves the limit of detection of RT-LAMP to levels**

239 **similar to qRT-PCR**

240 One of the primary reasons the direct RT-LAMP assay is less sensitive than the diagnostic qRT-

241 PCR assay is because the qRT-PCR assay uses 5 $\mu$ l of concentrated and purified RNA as input.

242 To determine whether the RT-LAMP assay would perform to a similar level of detection if the

243 same input was used, 5 $\mu$ l of purified RNA was used in RT-LAMP assays from a subset (n=44)

244 of COVID-19-positive NP swab samples. The viral loads ranged from  $1.01 \times 10^4$  to  $1.14 \times 10^{10}$ . 19

245 of 44 had concentrations of virus below the RT-LAMP LOD of  $1 \times 10^6$  vRNA copies/ml. Of the

246 44 samples tested with 1 $\mu$ l of direct swab, 18 tested positive (43%) and 7 were equivocal

247 between replicates (Fig 2B and S2 Table). When 5 $\mu$ l of purified RNA was used in the reactions

248 instead, 42 of 44 samples (95%) tested positive (Fig 2B, S2 Table). Furthermore, samples with

249 100-fold lower vRNA copies/ml were detected after RNA isolation by RT-LAMP. Adding

250 purified RNA brings the possible LOD of detection down to 50 copies of input of a 10 copy/ $\mu$ l

251 sample ( $1 \times 10^4$  copies/ml), which was detected in 4 of 6 primary samples tested within this viral  
252 load range. Overall, the addition of 1  $\mu$ l NP swab direct was associated with reduced odds of a  
253 positive RT-LAMP result (OR = 0.0054, 95% CI = 0.00023-0.041,  $p = 2.56 \times 10^{-5}$ ). Similar to the  
254 results for lysis buffer treatment, samples with qRT-PCR vRNA loads greater than  $1 \times 10^6$   
255 copies/ml had significantly increased odds of a positive RT-LAMP result (OR = 49.35, 95% CI =  
256 8.22-966.29,  $p = 0.00044$ ). Lastly, the C<sub>q</sub> values were lower for all detected samples when 5  $\mu$ l of  
257 RNA was added (mean C<sub>q</sub> = 31.42) instead of 1  $\mu$ l straight sample (mean C<sub>q</sub> = 58.72), indicating  
258 faster and more robust detection with concentrated and purified RNA (Wilcoxon signed rank  
259 test,  $V = 903$ ,  $p = 1.71 \times 10^{-8}$ ) (Fig 2B).

## 260 **Alternative primers improve efficiency**

261 Multiple SARS-CoV-2 RT-LAMP primer sets have been published or included in manuscripts  
262 on pre-print servers since we began our experiments. We compared the efficiency of several  
263 alternative primer sets either alone or in combination to the Gene-N-A primers used in our initial  
264 studies (S1 Table). Two primary NP swab samples with high concentrations of SARS-CoV-2  
265 (NP1:  $1.09 \times 10^{12}$  copies/ml, NP2:  $4.28 \times 10^{10}$  copies/ml) as well as gamma-irradiated SARS-CoV-2  
266 (BEI) were used to screen different primer combinations using the same fluorescent RT-LAMP  
267 conditions. First, a set of primers previously established (17, 27) and used to obtain an FDA  
268 EUA by Color Genomics was tested with each primer alone and in different combinations (Fig  
269 3A). Several primers and primer combinations resulted in a lower C<sub>q</sub> value across the board than  
270 the Gene-N-A gene primers suggesting improved reaction efficiency. The primer combinations  
271 including Color-N/Color-E and Color-N/Color-ORF1a yielded the lowest C<sub>q</sub> values in all  
272 samples.

273

274 **Fig 3: Comparison of RT-LAMP Cq value on primary NP swab samples, irradiated SARS-**  
275 **CoV-2 or SARS-CoV-2 TWIST RNA amplified with different primer sets.** Reactions were  
276 run in duplicate and both replicates are shown on the graphs. Samples that were not detectable  
277 are plotted on the ND line at Cq 80. A. Comparison of Cq values using Color Genomics primers  
278 to the Gene-N-A primers on two primary NP swab samples and irradiated SARS-CoV-2. B.  
279 Comparison of Zhang et al.(25) primers to a subset of Color Genomics primers and Gene-N-A  
280 primers on two primary samples and irradiated SARS-CoV-2. C. Comparison of the Cq values  
281 obtained when using the best primers and combinations of primers across different dilutions of  
282 SARS-CoV-2 TWIST RNA with and without GuHCl.

283

284 Next, we compared the Gene-N-A, Color-N, Color-E, and Color-N/E combination to  
285 second generation primers described in Zhang et al. (25) (Gene-N2, Gene-E1 and As1e). We  
286 found that As1e, originally published by Rabe et al. (26) yielded the lowest Cq value followed  
287 closely by a combination of As1e with the two primers targeting the Gene-N2 and Gene-E1  
288 genes designed by Zhang et al. (Fig 3B). The Color-N primer yielded similar Cq values to the  
289 triple combination primer set from Zhang et al. We also tested the Color-N, Color-E1, and Gene-  
290 N-A gene primer sets against additional published primers that target ORF1a (Lamb, Yu, El-  
291 Tholoth, and Zhang primers) either alone or in combination and compared them to the Gene-N-A  
292 gene primer set (S1 Table). The Color-N primer produced the lowest Cq value in this set (S1  
293 Fig).

294 We then tested As1e, Color-N, As1e/Color-N/Gene-E1 primer set with and without  
295 guanidine hydrochloride, as recommended by Zhang et al., with Twist RNA SARS-CoV-2

296 template. Under these conditions, guanidine hydrochloride improved detection with most primer  
297 sets with the exception of the Gene-N-A primer set (Fig 3C). Using the Twist RNA, the primer  
298 set that detected samples at the lowest dilutions was the Color-N primer or combination of  
299 As1e/Color-N/Gene-E1 with guanidine hydrochloride, though only in one of two replicates. The  
300 As1e primer with and without GuHCl as well as the combination As1e/Color-N/Gene-E1 with  
301 GuHCl often yielded the lowest C<sub>q</sub> value.

302 Lastly, to determine which primer set or combination worked best with primary NP swab  
303 samples, fourteen samples with viral loads ranging from  $7.33 \times 10^7$ - $1.52 \times 10^{11}$  vRNA copies/ml  
304 were tested using 1 $\mu$ l of straight swab sample with the most promising primer combinations with  
305 and without GuHCl. Both the Color-N primer set alone and the As1e/Color-N/Gene-E1  
306 combination yielded the lowest C<sub>q</sub> value across the different levels of virus (Fig 4A). Guanidine  
307 hydrochloride did not improve detection in primary samples as seen with the Twist RNA.  
308 Twelve additional primary NP swab samples with high Ct values ranging from 25 to 35 were  
309 tested with the Color-N and As1e/Color-N/Gene-E1 combination. Detection of these samples  
310 was very similar between the two primer conditions (Fig 4B).

311

312 **Fig 4: Comparison of the best-performing primers and combinations on additional**  
313 **primary NP swab samples with varying levels of virus with and without GuHCl. A.**

314 Comparison of three primer sets or combinations either with or without GuHCl on 14 primary  
315 NP swab samples with high viral load copy numbers. B. Comparison of the Color-N primer set  
316 to As1e/Color-N/Gene-E1 on primary NP swab samples with lower levels of virus. These  
317 samples were not run by our in-house viral load test and therefore Ct value obtained from the  
318 hospital is reported.

319

## 320 **Transition to saliva-based direct RT-LAMP**

321 To best accommodate point-of-need testing, saliva-based tests using colorimetric read-out  
322 minimizes expensive equipment and eases sample collection. We modified our direct RT-LAMP  
323 approach to accommodate detection of SARS-CoV-2 from saliva while also incorporating heat  
324 inactivation of the virus for safety in the field (32). Leftover paired NP swab and saliva samples  
325 were tested by their respective RT-LAMP protocols as well as by qRT-PCR (Fig 5). Detection of  
326 SARS-CoV-2 by RT-LAMP was dependent on the viral load of the sample rather than the  
327 starting sample material. Overall, samples with viral loads above  $5 \times 10^5$  copies/ml were detected  
328 as positive by RT-LAMP from either NP swab or saliva. Viral loads from NP swab samples were  
329 often higher than those in saliva in this sample set. This is likely due to the saliva samples being  
330 stored for 2-4 weeks at 4°C before use in this assay while NP swabs were stored for 1-2 weeks at  
331 4°C and then were frozen before use. This data should not be used to assess differences in viral  
332 load observed between saliva and NP swabs because of the differential storage of these leftover  
333 samples. This data does provide proof-of-concept that saliva can be added directly to  
334 colorimetric RT-LAMP reactions and yields a LOD similar to NP swab samples.

335

336 **Fig 5: Colorimetric RT-LAMP from SARS-CoV-2 positive paired NP swab and saliva**  
337 **samples.** Positive samples are yellow and negative samples are red. qRT-PCR-based viral loads  
338 are presented above each sample pair. Paired numbers are from the same patient. Some saliva  
339 samples did not have paired NP swab samples. Irradiated SARS-CoV-2 was used as a positive  
340 control.



## 341 **Discussion**

342 Frequent, widespread testing is considered the best mitigation strategy to control SARS-CoV-2  
343 before a vaccine or effective therapeutic is available. Traditional qRT-PCR is relatively sensitive,  
344 but it is time consuming and reliant on very specific reagents that are in short supply in the  
345 ongoing pandemic. RT-LAMP has become a promising alternative to qRT-PCR, but the true  
346 sensitivity of this assay has been poorly characterized from primary NP swab samples when  
347 added directly into the reaction. Many published studies establish a LOD based on free RNA  
348 transcript or isolated RNA from cultured virus of around 100 copies/rxn. These LODs apply to  
349 RT-LAMP only when purified RNA is used as input. They do not apply to direct RT-LAMP  
350 methods containing whole virions in primary samples also containing host enzymes and other  
351 host components. In this study we established that 625 copies/reaction was necessary in order to  
352 detect RNA transcripts consistently in 9/10 reactions in our assay. In primary samples we rarely  
353 detected virus in samples with a vRNA load of less than  $5 \times 10^5$ - $1 \times 10^6$  vRNA copies/ml,  
354 establishing this threshold as a conservative LOD. While not as sensitive as methods with RNA  
355 extraction first, this LOD range is sufficient for SARS-CoV-2 surveillance to detect virus in  
356 individuals with the minimal amount of virus necessary to isolate the virus and therefore most  
357 likely to transmit the virus.

358         The LOD of  $1 \times 10^6$  copies/ml is likely due to inefficiencies associated with virus lysis at  
359  $65^\circ\text{C}$  during the LAMP reaction and possible degradation of liberated RNA by enzymes,  
360 including RNases, present in primary samples. Indeed, adding more sample, including more host  
361 enzymes and media with potential inhibitors, reduced detection. On the other hand, lysis with  
362 LucigenQE was compatible with RT-LAMP and improved our sensitivity to detect SARS-CoV-2  
363 in primary samples with vRNA loads less than  $10^6$  copies/ml. When compared with direct

364 addition, we were able to increase our detection of true positives for both replicates from 61% to  
365 78% after lysis treatment. Guanidine hydrochloride has also been shown to improve sensitivity in  
366 other studies and while our results showed better detection with synthetic Twist RNA, bringing  
367 the LOD down to 62.5 copies/ $\mu$ l, the same improvement was not observed in primary samples  
368 with intact virus. The largest increase in sensitivity occurred with RNA isolation prior to RT-  
369 LAMP using an alternative RNA isolation method to those approved for the CDC qRT-PCR  
370 assay. With RNA isolation we detected 95% of the samples detected by qRT-PCR, including  
371 those with the lowest viral loads.

372         There are now many primers available targeting different regions of SARS-CoV-2. In  
373 this work we tested several sets to iteratively choose which primer set worked best with primary  
374 NP swab samples. We found that several primer sets performed more efficiently than the Gene-  
375 N-A primers we used in most of our experiments. The two best performing primer sets that were  
376 nearly indistinguishable in performance with both high and low viral load primary samples were  
377 a combination of As1e/Color-N/Gene E1 and the Color-N primer set alone.

378         For most of this study we chose to use fluorescent RT-LAMP for detection rather than  
379 colorimetric detection. Using fluorescence enabled analysis of the differences in the Cq values  
380 providing a quantitative evaluation of how each condition changed the efficiency of the assay.  
381 However, when considering how to deploy RT-LAMP in the field, our group has developed a  
382 mobile RT-LAMP workflow that uses saliva and colorimetric readouts for low cost and  
383 portability. Additional work needs to be done to determine whether the benefits of fluorescent  
384 detection can be inexpensively migrated to decentralized point-of-need testing.

385         Many studies are comparing RT-LAMP to RT-PCR results presented as Ct value, rather  
386 than vRNA copies/ml. We chose to focus on comparing methods and determining LODs based

387 on a standard qRT-PCR assay performed in our laboratory with a quantitative standard, rather  
388 than Ct values generated by the varying sources of our primary samples. The hospital  
389 laboratories have transitioned between different methods as reagents were available and as new  
390 assays became available, which means that the Ct values we obtained for each of our samples  
391 was generated by different assays targeting different regions of the SARS-CoV-2 genome. By  
392 comparing all our results to the vRNA copies/ml that we generated in our lab using a consistent  
393 primer set and protocol (CDC qRT-PCR assay) that targeted the same gene (and primers) as our  
394 SARS-CoV-2 RT-LAMP assay, we were able to ensure our comparisons were consistent across  
395 all samples.

396 Overall, we have shown that direct RT-LAMP using fluorescent detection can detect  
397 SARS-CoV-2 in primary NP swab samples with viral loads greater than  $1 \times 10^6$  vRNA copies/ml.  
398 We were able to improve this slightly with the quick and low-cost addition of Lucigen lysis  
399 buffer to the reaction. We also saw improvement in efficiency with several alternative primer  
400 sets. While direct RT-LAMP is not as sensitive as qRT-PCR, the gold standard for diagnosis, it  
401 is sufficient to detect the levels of virus that are necessary to culture virus from a sample as  
402 described previously. This means that this assay detects people who are likely to transmit the  
403 virus for a significant reduction in cost, time, and reagents relative to qRT-PCR. One proposed  
404 way to utilize this test could be to screen large numbers of individuals who are then directed  
405 toward diagnostic testing by qRT-PCR if they test positive by this test, significantly reducing the  
406 burden on diagnostic labs and their resources. Lastly, we confirmed that saliva was also  
407 compatible with direct RT-LAMP assays when heated first to inactivate the virus and nucleases.  
408 Overall, direct RT-LAMP is an important addition to the repertoire of currently available tests to  
409 identify samples containing SARS-CoV-2 nucleic acids.

## 410 **Acknowledgements**

411 We thank Nathan Tanner for discussions about primers and optimizations of the RT-LAMP  
412 assay. The following reagent was deposited by the Centers for Disease Control and Prevention  
413 and obtained through BEI resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-  
414 WA1/2020, Gamma-Irradiated, NR-52287.

415

## 416 **References**

- 417 1. Arons MM, Hatfield KM, Reddy SC et al. Presymptomatic SARS-CoV-2 Infections and  
418 Transmission in a Skilled Nursing Facility. *N Engl J Med.* 2020;382:2081-2090.
- 419 2. Rothe C, Schunk M, Sothmann P et al. Transmission of 2019-nCoV Infection from an  
420 Asymptomatic Contact in Germany. *N Engl J Med.* 2020;382:970-971.
- 421 3. Meng H, Xiong R, He R et al. CT imaging and clinical course of asymptomatic cases with  
422 COVID-19 pneumonia at admission in Wuhan, China. *J Infect.* 2020
- 423 4. Lavezzo E, Franchin E, Ciavarella C et al. Suppression of a SARS-CoV-2 outbreak in the  
424 Italian municipality of Vo'. *Nature.* 2020;584:425-429.
- 425 5. Zou L, Ruan F, Huang M et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens  
426 of Infected Patients.[letter]. *N Engl J Med* 2020;382(12):1177-1179.
- 427 6. Lee S, Kim T, Lee E et al. Clinical Course and Molecular Viral Shedding Among  
428 Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community  
429 Treatment Center in the Republic of Korea. *JAMA Internal Medicine.* 2020
- 430 7. Wölfel R, Corman VM, Guggemos W et al. Virological assessment of hospitalized patients  
431 with COVID-2019. *Nature.* 2020;581:465-469.

- 432 8. Lescure FX, Bouadma L, Nguyen D et al. Clinical and virological data of the first cases of  
433 COVID-19 in Europe: a case series. *Lancet Infect Dis.* 2020;20:697-706.
- 434 9. Munster VJ, Feldmann F, Williamson BN et al. Respiratory disease and virus shedding in  
435 rhesus macaques inoculated with SARS-CoV-2. *bioRxiv.* 2020
- 436 10. Van Kampen JJ, van de Vijver DA, Fraaij PL et al. Shedding of infectious virus in  
437 hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key  
438 determinants. *medRxiv.* 2020
- 439 11. Quicke K, Gallichote E, Sexton N et al. Longitudinal Surveillance for SARS-CoV-2 RNA  
440 Among Asymptomatic Staff in Five Colorado Skilled Nursing Facilities: Epidemiologic,  
441 Virologic and Sequence Analysis. *medRxiv.* 2020
- 442 12. La Scola B, Le Bideau M, Andreani J et al. Viral RNA load as determined by cell culture  
443 as a management tool for discharge of SARS-CoV-2 patients from infectious disease  
444 wards. *Eur J Clin Microbiol Infect Dis.* 2020;39:1059-1061.
- 445 13. Wu KJ. 'It's Like Groundhog Day': Coronavirus Testing Labs Again Lack Key Supplies.  
446 2020
- 447 14. Vogels CB, Brackney D, Wang J et al. SalivaDirect: Simple and sensitive molecular  
448 diagnostic test for SARS-CoV-2 surveillance. *MedRxiv.* 2020
- 449 15. Park GS, Ku K, Baek SH et al. Development of Reverse Transcription Loop-Mediated  
450 Isothermal Amplification Assays Targeting Severe Acute Respiratory Syndrome  
451 Coronavirus 2 (SARS-CoV-2). *J Mol Diagn.* 2020;22:729-735.
- 452 16. Zhang Y, Odiwuor N, Xiong J et al. Rapid Molecular Detection of SARS-CoV-2 (COVID-  
453 19) Virus RNA Using Colorimetric LAMP. 2020

- 454 17. Lamb LE, Bartolone SN, Ward E, Chancellor MB. Rapid detection of novel  
455 coronavirus/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse  
456 transcription-loop-mediated isothermal amplification. *PLoS One*. 2020;15:e0234682.
- 457 18. Mahony J, Chong S, Bulir D, Ruyter A, Mwawasi K, Waltho D. Multiplex loop-mediated  
458 isothermal amplification (M-LAMP) assay for the detection of influenza A/H1, A/H3 and  
459 influenza B can provide a specimen-to-result diagnosis in 40 min with single genome copy  
460 sensitivity. *J Clin Virol*. 2013;58:127-131.
- 461 19. Baek YH, Um J, Antigua KJC et al. Development of a reverse transcription-loop-mediated  
462 isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. *Emerg*  
463 *Microbes Infect*. 2020;9:998-1007.
- 464 20. Huang WE, Lim B, Hsu CC et al. RT-LAMP for rapid diagnosis of coronavirus SARS-  
465 CoV-2. *Microb Biotechnol*. 2020;13:950-961.
- 466 21. Kitagawa Y, Orihara Y, Kawamura R et al. Evaluation of rapid diagnosis of novel  
467 coronavirus disease (COVID-19) using loop-mediated isothermal amplification. *J Clin*  
468 *Virol*. 2020;129:104446.
- 469 22. Lu R, Wu X, Wan Z, Li Y, Jin X, Zhang C. A Novel Reverse Transcription Loop-Mediated  
470 Isothermal Amplification Method for Rapid Detection of SARS-CoV-2. *Int J Mol Sci*.  
471 2020;21
- 472 23. Lu R, Wu X, Wan Z et al. Development of a Novel Reverse Transcription Loop-Mediated  
473 Isothermal Amplification Method for Rapid Detection of SARS-CoV-2.[letter]. *Virol Sin*  
474 2020;35(3):344-347.

- 475 24. Yan C, Cui J, Huang L et al. Rapid and visual detection of 2019 novel coronavirus (SARS-  
476 CoV-2) by a reverse transcription loop-mediated isothermal amplification assay. *Clin*  
477 *Microbiol Infect.* 2020;26:773-779.
- 478 25. Zhang Y, Ren G, Buss J, Barry AJ, Patton GC, Tanner NA. Enhancing colorimetric loop-  
479 mediated isothermal amplification speed and sensitivity with guanidine chloride.  
480 *Biotechniques.* 2020
- 481 26. Rabe BA, Cepko C. SARS-CoV-2 Detection using an isothermal amplification reaction and  
482 a rapid, inexpensive protocol for sample inactivation and purification. *medRxiv.* 2020
- 483 27. Broughton JP, Deng X, Yu G et al. CRISPR-Cas12-based detection of SARS-CoV-2. *Nat*  
484 *Biotechnol.* 2020;38:870-874.
- 485 28. El-Tholoth M, Bau HH, Song J. A single and two-stage, closed tube, molecular test for the  
486 2019 novel coronavirus (COVID-19) at home, clinic, and points of entry. *ChemRxiv.* 2020
- 487 29. Yu L, Wu S, Hao X et al. Rapid Detection of COVID-19 Coronavirus Using a Reverse  
488 Transcriptional Loop-Mediated Isothermal Amplification (RT-LAMP) Diagnostic  
489 Platform.[letter]. *Clin Chem* 2020;66(7):975-977.
- 490 30. Ladha A, Joung J, Abudayyeh O, Gootenberg J, Zhang F. A 5-min RNA preparation  
491 method for COVID-19 detection with RT-qPCR. *medRxiv.* 2020
- 492 31. Team RC. R: A language and environment for statistical computing. 2017
- 493 32. Newman CM, Dudley DM, Wiseman RW et al. Initial evaluation of a mobile SARS-CoV-2  
494 RT-LAMP testing strategy. *MedRxiv.* 2020
- 495
- 496
- 497

## 498 **Supporting information captions**

499 **S1 Figure. Comparison of Gene-N-A, Color-N, and Color-E primers to several ORF1a -**  
500 **targeting primer sets and combinations with two primary samples and irradiated SARS-**  
501 **CoV-2. Samples that were not detectable were plotted on the ND line set at Cq 80, the highest**  
502 **cycle number in our assay.**

503

504 **S1 Table. Primer sequences and final 1X concentrations used in the RT-LAMP reactions.**


505

506 **S2 Table. qRT-PCR N-gene viral loads and RT-LAMP Cq values from 106 primary NP**  
507 **swab samples run in duplicate with 1ul of swab sample or a subset of NP swab samples run**  
508 **in duplicate with either 1ul of primary samples treated with Lucigen QuickExtract or 5ul**  
509 **of extracted vRNA.**


510




A.





B.




C.







A.




B.




C.



A.



B.



Saliva

NP swab

